CL2013000481A1 - Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas. - Google Patents
Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.Info
- Publication number
- CL2013000481A1 CL2013000481A1 CL2013000481A CL2013000481A CL2013000481A1 CL 2013000481 A1 CL2013000481 A1 CL 2013000481A1 CL 2013000481 A CL2013000481 A CL 2013000481A CL 2013000481 A CL2013000481 A CL 2013000481A CL 2013000481 A1 CL2013000481 A1 CL 2013000481A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmacotherapy
- efficacy
- administration
- improve
- reduce
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40170610P | 2010-08-18 | 2010-08-18 | |
US40170510P | 2010-08-18 | 2010-08-18 | |
US40170710P | 2010-08-18 | 2010-08-18 | |
US40171210P | 2010-08-18 | 2010-08-18 | |
US40170910P | 2010-08-18 | 2010-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2013000481A1 true CL2013000481A1 (es) | 2013-11-22 |
Family
ID=45605648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2013000481A CL2013000481A1 (es) | 2010-08-18 | 2013-02-18 | Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9066918B2 (es) |
EP (2) | EP3246026A3 (es) |
JP (1) | JP2013537552A (es) |
KR (1) | KR20140022750A (es) |
CN (2) | CN107441493A (es) |
AU (2) | AU2011292044A1 (es) |
BR (1) | BR112013003671A2 (es) |
CA (1) | CA2808626A1 (es) |
CL (1) | CL2013000481A1 (es) |
MX (1) | MX2013001858A (es) |
SG (2) | SG10201802116RA (es) |
WO (1) | WO2012024367A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9630938B2 (en) | 2010-08-18 | 2017-04-25 | Delmar Pharmaceuticals, Inc. | Method of synthesis of substituted hexitols such as dianhydrogalactitol |
US9085544B2 (en) | 2010-08-18 | 2015-07-21 | Del Mar Pharmaceuticals | Method of synthesis of substituted hexitols such as dianhydrogalactitol |
US9901563B2 (en) * | 2013-03-11 | 2018-02-27 | Delmar Pharmaceuticals, Inc. | Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol |
EP2758043A4 (en) * | 2011-08-17 | 2016-02-24 | Dennis M Brown | COMPOSITIONS AND METHODS FOR INCREASING THE THERAPEUTIC UTILITY OF SUBOPTIMALLY APPLIED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIBROMODULCITOL |
CN110711188A (zh) * | 2012-01-20 | 2020-01-21 | 德玛公司 | 经取代的己糖醇类用于治疗恶性肿瘤的用途 |
CN102626412B (zh) * | 2012-03-23 | 2014-01-15 | 武汉大学 | 一种治疗恶性肿瘤的药物组合物 |
US9814693B2 (en) * | 2012-05-09 | 2017-11-14 | Delmar Pharmaceuticals, Inc. | Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies |
SG10201610869TA (en) * | 2012-06-26 | 2017-02-27 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalacti |
US8987469B2 (en) | 2012-07-24 | 2015-03-24 | Heyl Chemisch-Pharmazeutische Fabrik Gmbh & Co. Kg | Process for the preparation of bendamustine |
AU2014251038A1 (en) * | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
TW201536278A (zh) * | 2013-05-31 | 2015-10-01 | Del Mar Pharmaceuticals | 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途 |
US20160067241A1 (en) * | 2013-06-13 | 2016-03-10 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
WO2015013581A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
KR101561345B1 (ko) * | 2013-10-17 | 2015-10-16 | 대원제약주식회사 | 제어방출되는 프로피온산 계열의 약제학적 조성물 |
KR101511857B1 (ko) | 2013-11-01 | 2015-04-13 | 주식회사 엘지생활건강 | 디메틸 칸타리딘을 유효성분으로 포함하는 체모성장 저해용 조성물 |
KR102359214B1 (ko) * | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
BR112017009845A2 (pt) * | 2014-11-10 | 2018-01-16 | Del Mar Pharmaceuticals | dianidrogalactitol juntamente com radiação para tratar carcinoma de célula não pequena dos pulmões e glioblastoma multiforme |
CN105031284A (zh) * | 2015-08-31 | 2015-11-11 | 王学宽 | 治疗口腔白斑病的口服药剂 |
CN105663072B (zh) * | 2016-02-23 | 2018-09-28 | 广西梧州制药(集团)股份有限公司 | 一种去水卫矛醇薄膜包衣片及其制备方法 |
CN105663060B (zh) * | 2016-02-23 | 2018-08-14 | 广西梧州制药(集团)股份有限公司 | 一种去水卫矛醇脂质体冻干粉针剂及其制备方法 |
CN105663076A (zh) * | 2016-02-23 | 2016-06-15 | 广西梧州制药(集团)股份有限公司 | 一种起效快防潮好的去水卫矛醇薄膜包衣片及其制备方法 |
CN107463784B (zh) * | 2017-08-16 | 2020-12-08 | 华东理工大学 | 一种苯乙烯设备选型规则生成方法 |
US11965206B2 (en) | 2018-12-21 | 2024-04-23 | John Stoddard | Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU172826B (hu) * | 1974-12-24 | 1978-12-28 | Mta Koezponti Kemiai Kutato In | Sposob poluchenija novykh acilnykh proizvodnykh 1,2-5,6-diangidro-geksitov s protivoopukholevoj aktivnost'ju |
HU182227B (en) * | 1980-11-04 | 1983-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing hexitols containing free carboxyl group |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US6011069A (en) | 1995-12-26 | 2000-01-04 | Nisshin Flour Milling Co., Ltd. | Multidrug resistance inhibitors |
US6057367A (en) * | 1996-08-30 | 2000-05-02 | Duke University | Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses |
CA2319495A1 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
EP1104297B8 (en) | 1998-07-09 | 2006-05-03 | Cephalon, Inc. | Compositions for the treatment of chronic lymphocytic leukemia |
US6921722B2 (en) | 2000-05-30 | 2005-07-26 | Ebara Corporation | Coating, modification and etching of substrate surface with particle beam irradiation of the same |
US20020037328A1 (en) * | 2000-06-01 | 2002-03-28 | Brown Dennis M. | Hexitol compositions and uses thereof |
CN1116875C (zh) | 2000-10-19 | 2003-08-06 | 南京振中生物工程有限公司 | 紫杉醇脂质组合物及其制备方法 |
US7619005B2 (en) | 2000-11-01 | 2009-11-17 | Cognition Pharmaceuticals Llc | Methods for treating cognitive impairment in humans with Multiple Sclerosis |
ES2554106T3 (es) | 2001-06-21 | 2015-12-16 | Genentech, Inc. | Formulación de liberación sostenida |
DE60329126D1 (de) | 2002-02-20 | 2009-10-15 | Beth Israel Hospital | Konjugate mit biologisch abbaubarem polymer und verwendung dafür |
US7101576B2 (en) | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
EP1620120A4 (en) | 2003-03-24 | 2010-01-06 | Sequoia Pharmaceuticals Inc | BIOLOGICAL ACTIVE CONJUGATES WITH LONG-TERM EFFECT |
US7446122B2 (en) | 2003-10-02 | 2008-11-04 | Cephalon, Inc. | Substituted indole derivatives |
HUP0303313A2 (hu) | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
US20080176923A1 (en) * | 2003-12-18 | 2008-07-24 | Salama Zoser B | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors |
WO2006012213A2 (en) * | 2004-06-25 | 2006-02-02 | Tea Guard Llc | Composition and method for delivery of phytochemicals |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
US20090318561A1 (en) * | 2008-06-23 | 2009-12-24 | Mutual Pharmaceutical Company, Inc. | Colchicine products, method of manufacture, and methods of use |
-
2011
- 2011-08-17 JP JP2013524950A patent/JP2013537552A/ja active Pending
- 2011-08-17 MX MX2013001858A patent/MX2013001858A/es not_active Application Discontinuation
- 2011-08-17 CN CN201710574963.6A patent/CN107441493A/zh active Pending
- 2011-08-17 KR KR1020137006881A patent/KR20140022750A/ko not_active Application Discontinuation
- 2011-08-17 AU AU2011292044A patent/AU2011292044A1/en not_active Abandoned
- 2011-08-17 SG SG10201802116RA patent/SG10201802116RA/en unknown
- 2011-08-17 CN CN2011800501692A patent/CN103476250A/zh active Pending
- 2011-08-17 WO PCT/US2011/048031 patent/WO2012024367A2/en active Search and Examination
- 2011-08-17 EP EP17173607.7A patent/EP3246026A3/en not_active Withdrawn
- 2011-08-17 SG SG2013011937A patent/SG188234A1/en unknown
- 2011-08-17 CA CA2808626A patent/CA2808626A1/en not_active Abandoned
- 2011-08-17 BR BR112013003671A patent/BR112013003671A2/pt not_active IP Right Cessation
- 2011-08-17 US US13/817,096 patent/US9066918B2/en active Active
- 2011-08-17 EP EP11818706.1A patent/EP2605650A4/en not_active Ceased
-
2013
- 2013-02-18 CL CL2013000481A patent/CL2013000481A1/es unknown
-
2016
- 2016-09-14 AU AU2016228194A patent/AU2016228194A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SG188234A1 (en) | 2013-04-30 |
CA2808626A1 (en) | 2012-02-23 |
AU2016228194A1 (en) | 2016-10-06 |
WO2012024367A2 (en) | 2012-02-23 |
US9066918B2 (en) | 2015-06-30 |
US20130289107A1 (en) | 2013-10-31 |
EP2605650A4 (en) | 2014-05-21 |
EP3246026A3 (en) | 2018-02-21 |
EP3246026A2 (en) | 2017-11-22 |
BR112013003671A2 (pt) | 2017-01-10 |
EP2605650A2 (en) | 2013-06-26 |
AU2011292044A1 (en) | 2013-04-04 |
JP2013537552A (ja) | 2013-10-03 |
CN107441493A (zh) | 2017-12-08 |
SG10201802116RA (en) | 2018-04-27 |
CN103476250A (zh) | 2013-12-25 |
MX2013001858A (es) | 2013-09-13 |
KR20140022750A (ko) | 2014-02-25 |
WO2012024367A3 (en) | 2012-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013000481A1 (es) | Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas. | |
AR124134A2 (es) | Formulación de uso tópico para un inhibidor de jak | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CL2015000345A1 (es) | Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. | |
CL2014000732A1 (es) | Compuestos derivados heterociclicos para su uso en la prevencion o tratamiento de una infeccion por flavivirus; metodo para su preparacion; y composicion farmaceutica que los comprende. | |
CL2014000365A1 (es) | Compuesto 4-(8-metoxi-1-((r)-1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol, inhibidor de brodominio; composicion farmaceutica; producto farmaceutico; procedimiento de tratamiento; y su uso para tratar una afeccion autoinmune y/o inflamatoria cronica y cancer, entre otras. | |
CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
CL2014001450A1 (es) | Forma de dosis de liberacion controlada solida que comprende un analgesico opioide dispersado en un material de matriz; metodo de preparacion; uso en el tratamiento del dolor. | |
BR112013033940A2 (pt) | terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer | |
CL2012000319A1 (es) | Uso de una composición farmaceutica que comprende treprostinil para la preparación de un medicamento para el tratamiento o la prevención de una afección asociada a la fibrosis quística. | |
BR112013011480A8 (pt) | método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer | |
CL2011002595A1 (es) | Uso de una combinacion de un agente anticancerigeno y un antioxidante para tratar el cancer; y compicicion farmaceutica que comprende dicha combinacion. | |
AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
CL2014001016A1 (es) | Compuestos triciclicos condensados y sus sales farmaceuticamente aceptables; composicion farmaceutica que los comprende; y su uso en el tratamiento de una infeccion viral. | |
GT201200304A (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
CO6801754A2 (es) | Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida | |
CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. | |
CL2015000375A1 (es) | Composicion farmaceutica en forma de microparticulas que comprende un nucleo inerte y al menos una primera capa de principio activo; proceso de formacion de microparticulas; combinacion farmaceutica; kit farmaceutico; uso para tratar y/o prevenir edemas, enfermedades cardiovasculares, diabetes, hipertension, entre otras. | |
CL2013001564A1 (es) | Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica. | |
CL2013000895A1 (es) | Combinacion farmaceutica que comprende un compuesto derivado de imidazo[4,5-c]-quinolina, inhibidor de pik3/mtor, un compuesto alosterico inhibidor de mtor y opcionalmente un vehiculo farmaceuticamente aceptable; composicion farmaceutica; metodo para mejorar la eficacia del tratamiento; y su uso en una enfermedad proliferativa. | |
CL2014000267A1 (es) | Formulacion farmaceutica liquida que comprende ketoprofeno, amitriptilina y oximetazolina; kit farmaceutico; metodo para prevenir o tratar la inflamacion. | |
BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
DOP2016000003A (es) | Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán |